StockData
RedHill Biopharma Ltd. logo

RedHill Biopharma Ltd. (RDHL) stock

RDHLNasdaqPharmaceutical Preparations
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Apr 27, 2026Score 0/30
$0.35−0.01 (-2.91%)

Close on Nov 17, 2026Market cap $1.78MP/E –Yield –

Earnings

RedHill Biopharma's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
–
Not yet scheduled
Revenue
–
EPS
–
Latest guidance
None
No outlook given in releases

Quarterly results

Revenue and earnings per share from each of RedHill Biopharma's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q2 FY2026ended Jun 30, 2026Sep 30, 2026after the close–––Release
Q2 FY2025ended Jun 30, 2025Sep 5, 2025before the open–––Release
Q2 FY2023ended Jun 30, 2023Aug 17, 2023before the open–––Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Guidance

RedHill Biopharma has not given guidance in its releases

Many companies give their outlook only on the conference call or not at all. When RedHill Biopharma puts a forecast in an earnings release, it is listed here with the exact sentence.

Press releases

Releases RedHill Biopharma filed with the SEC as exhibits to Form 8-K or 6-K

  1. 6-K
  2. 6-K
  3. 6-K
  4. 6-K
  5. 6-K
  6. 6-K
  7. 6-K
  8. 6-K
  9. 6-K
  10. 6-K
  11. 6-K
  12. 6-K
  13. 6-K
  14. 6-K
  15. 6-K

See a number that looks wrong?